Sage Mountain Advisors LLC Takes $394,000 Position in IQVIA Holdings Inc. $IQV

Sage Mountain Advisors LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 2,077 shares of the medical research company’s stock, valued at approximately $394,000.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA during the second quarter valued at about $515,772,000. Norges Bank purchased a new stake in IQVIA during the 2nd quarter worth approximately $270,160,000. AQR Capital Management LLC raised its position in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC boosted its stake in shares of IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after buying an additional 774,681 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several recent analyst reports. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Mizuho set a $266.00 price target on IQVIA in a research note on Friday, January 9th. BMO Capital Markets began coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective on the stock. TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Finally, Barclays set a $230.00 price objective on IQVIA in a research note on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $249.19.

IQVIA Price Performance

Shares of NYSE IQV opened at $241.28 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The firm has a market capitalization of $41.09 billion, a PE ratio of 33.10, a P/E/G ratio of 2.38 and a beta of 1.36. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The business’s fifty day moving average price is $228.51 and its two-hundred day moving average price is $204.88.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.